Delcath Systems announces availability of press release on first patient dosed in HEPZATO Phase 2 trial

Delcath Systems, Inc.

Delcath Systems, Inc.

DCTH

0.00
  • Delcath Systems announced first patient dosed in a global Phase 2 trial of HEPZATO for liver-dominant metastatic breast cancer.
  • Randomized study compares HEPZATO plus standard of care versus standard of care alone in HER2-negative patients following prior treatment failure.
  • About 90 patients planned across more than 20 sites in the US and Europe; primary endpoint is hepatic progression-free survival.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607090800BIZWIRE_USPR_____20260709_BW141093) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.